Home » News » Page 21

News

Cost savings from use of biosimilars in rheumatology

Published on 2013/12/24

The treatment of rheumatoid arthritis provides a clear argument in favour of developing biosimilars and the need to collect sufficient pharmacological data to validate their bioequivalence and interch...

13 views

The cost of evergreening strategies

Published on 2013/12/19

The practice of evergreening, where pharmaceutical companies make small patentable changes to existing products with soon-to-expire patents, contributed to increased healthcare costs in Switzerland, a...

40 views

Interchangeability of gabapentin generic formulations in The Netherlands: summary of a comparative bioavailability study

Published on 2013/12/17

AbstractÂ The registration of generic formulations in the EU is governed by regulatory authorities in the respective European countries. Before a generic drug can be registered, bioequivalence to th...

197 views

Australia issues new biosimilars guidance

Published on 2013/12/12

Australiaâ€™s regulatory body, the Therapeutic Goods Administration (TGA) published specific guidance for biosimilars on its website on 30 July 2013. The purpose of the guidance, according to th...

12 views

India to make prescribing of generics compulsory

Published on 2013/12/10

A parliamentary panel is proposing that the Indian Government should bring in legislation that would make it compulsory for doctors to prescribe only low cost generic drugs. The Parliamentary Standin...

18 views

Authorized generics reduce drug prices

Published on 2013/12/05

In what seems to be a bit of a turnaround for the US Federal Trade Commission (FTC), the agency has released a report which suggests that authorized generics can reduce both retail and wholesale drug ...

19 views

Celltrion applies for biosimilar infliximab approval in Japan

Published on 2013/12/03

On 11 September 2013, South Korean biotechnology company Celltrion announced that it had filed for approval of Remsima, its biosimilar infliximab monoclonal antibody, with Japanâ€™s Ministry of H...

38 views

Fight continues over biosimilar naming standards

Published on 2013/11/28

Biosimilar products marketed in the US should share the same common non-proprietary name as the reference brand-name biological medicine, according to the Generic Pharmaceutical Association (GPhA). ...

65 views

Naming requirements in Australian biosimilars guidance

Published on 2013/11/26

Australiaâ€™s drug regulatory agency, the Therapeutic Goods Administration (TGA), published specific guidance for biosimilars on its website on 30 July 2013. Included in this guidance is a sectio...

23 views

Canada clarifies regulatory pathway for subsequent entry low molecular weight heparins

Published on 2013/11/21

Canadaâ€™s regulatory agency, Health Canada, is asking drugmakers seeking approval of similar drugs containing low molecular weight heparins (LMWHs) to use the approval pathway for subsequent ent...

16 views

EU guidelines for nanosimilars

Published on 2013/11/19

Last update: Â 5 November 2013Â The regulatory body for approval of medicines in the European Union (EU) is the European Medicines Agency (EMA). The agency is responsible for the scientific eval...

93 views

WHO naming of biosimilars

Published on 2013/11/14

The World Health Organization (WHO) has proposed a system of naming for biosimilars, which has been commended by some groups, but criticized by others. The International Nonproprietary Name (INN) s...

27 views